Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis
Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus Leishmania includes a number of protozoan paras...
Main Author: | |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
Dove Medical Press
2019
|
Subjects: | |
Online Access: | https://doaj.org/article/f63e0c37a29544df83f5c223e9cf628d |
id |
ftdoajarticles:oai:doaj.org/article:f63e0c37a29544df83f5c223e9cf628d |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:f63e0c37a29544df83f5c223e9cf628d 2023-05-15T15:11:27+02:00 Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis Shirzadi MR 2019-04-01T00:00:00Z https://doaj.org/article/f63e0c37a29544df83f5c223e9cf628d EN eng Dove Medical Press https://www.dovepress.com/lipsosomal-amphotericin-b-a-review-of-its-properties-function-and-use--peer-reviewed-article-RRTM https://doaj.org/toc/1179-7282 1179-7282 https://doaj.org/article/f63e0c37a29544df83f5c223e9cf628d Research and Reports in Tropical Medicine, Vol Volume 10, Pp 11-18 (2019) liposomal amphotericin B cutaneous leishmaniasis Leishmania Arctic medicine. Tropical medicine RC955-962 article 2019 ftdoajarticles 2022-12-31T03:33:17Z Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus Leishmania includes a number of protozoan parasites that cause a wide range of infections named leishmaniasis. Leishmaniasis may be appear in three clinical forms — cutaneous (CL), visceral, and mucocutaneous (MCL) — with variation in their presentation and severity: diffuse CL and post–kala-azar dermal leishmaniasis). The prevalent signs of CL are nonhealing ulcers on exposed skin, but infected patients may have other dermatologic symptoms. In the 1960s, amphotericin B deoxycholate was introduced as a second-line therapy for CL and MCL. However, widespread administration of the agent was prevented, due to its renal and systemic toxicity, high price, and obstacles to intravenous use in leishmaniasis-endemic regions. Amphotericin B binds to ergosterol in the photogenic cell membranes and causes changes in membrane permeability, leakage of ions, and finally cell death. Compared to amphotericin B deoxycholate, a higher dose of liposomal amphotericin B should be administered to show the treatment effect. A high percentage of liposomal amphotericin B is “fastened” in the liposome and not biologically effective. Amphotericin B deoxycholate has some toxic effects, and liposomal amphotericin B is meaningfully less toxic compared to it. Treatment options for CL are limited, due to variation in species causing CL and pharmacokinetic issues. Amphotericin B is effective against some particular forms of CL.Keywords: liposomal amphotericin B, cutaneous leishmaniasis, Leishmania Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Azar ENVELOPE(-63.733,-63.733,-64.983,-64.983) |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English |
topic |
liposomal amphotericin B cutaneous leishmaniasis Leishmania Arctic medicine. Tropical medicine RC955-962 |
spellingShingle |
liposomal amphotericin B cutaneous leishmaniasis Leishmania Arctic medicine. Tropical medicine RC955-962 Shirzadi MR Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
topic_facet |
liposomal amphotericin B cutaneous leishmaniasis Leishmania Arctic medicine. Tropical medicine RC955-962 |
description |
Mohammad Reza Shirzadi1,21Center for Communicable Diseases Control, Ministry of Health and Medical Education, Tehran, Iran; 2Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Science, Tehran, IranAbstract: The genus Leishmania includes a number of protozoan parasites that cause a wide range of infections named leishmaniasis. Leishmaniasis may be appear in three clinical forms — cutaneous (CL), visceral, and mucocutaneous (MCL) — with variation in their presentation and severity: diffuse CL and post–kala-azar dermal leishmaniasis). The prevalent signs of CL are nonhealing ulcers on exposed skin, but infected patients may have other dermatologic symptoms. In the 1960s, amphotericin B deoxycholate was introduced as a second-line therapy for CL and MCL. However, widespread administration of the agent was prevented, due to its renal and systemic toxicity, high price, and obstacles to intravenous use in leishmaniasis-endemic regions. Amphotericin B binds to ergosterol in the photogenic cell membranes and causes changes in membrane permeability, leakage of ions, and finally cell death. Compared to amphotericin B deoxycholate, a higher dose of liposomal amphotericin B should be administered to show the treatment effect. A high percentage of liposomal amphotericin B is “fastened” in the liposome and not biologically effective. Amphotericin B deoxycholate has some toxic effects, and liposomal amphotericin B is meaningfully less toxic compared to it. Treatment options for CL are limited, due to variation in species causing CL and pharmacokinetic issues. Amphotericin B is effective against some particular forms of CL.Keywords: liposomal amphotericin B, cutaneous leishmaniasis, Leishmania |
format |
Article in Journal/Newspaper |
author |
Shirzadi MR |
author_facet |
Shirzadi MR |
author_sort |
Shirzadi MR |
title |
Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
title_short |
Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
title_full |
Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
title_fullStr |
Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
title_full_unstemmed |
Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
title_sort |
lipsosomal amphotericin b: a review of its properties, function, and use for treatment of cutaneous leishmaniasis |
publisher |
Dove Medical Press |
publishDate |
2019 |
url |
https://doaj.org/article/f63e0c37a29544df83f5c223e9cf628d |
long_lat |
ENVELOPE(-63.733,-63.733,-64.983,-64.983) |
geographic |
Arctic Azar |
geographic_facet |
Arctic Azar |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Research and Reports in Tropical Medicine, Vol Volume 10, Pp 11-18 (2019) |
op_relation |
https://www.dovepress.com/lipsosomal-amphotericin-b-a-review-of-its-properties-function-and-use--peer-reviewed-article-RRTM https://doaj.org/toc/1179-7282 1179-7282 https://doaj.org/article/f63e0c37a29544df83f5c223e9cf628d |
_version_ |
1766342297168904192 |